Sale

Schizophrenia Drugs Market

Global Schizophrenia Drugs Market Share, Size, Analysis: By Therapeutic Class: Second-generation Antipsychotics, Third-generation Antipsychotics, Other; By Route of Administration: Oral, Injectables; By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Schizophrenia Drugs Market Outlook

The value of the global schizophrenia drugs market was USD 8.18 billion in 2023, driven by the prevalence of schizophrenia across the globe. The market is expected to grow at a CAGR of 3.9% during the forecast period of 2024-2032 to reach value of USD 11.56 billion by 2032.

 

schizophrenia drugs market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Schizophrenia Drugs Market Trends

Schizophrenia is a chronic brain disorder that affects a person’s ability to think, feel, and act. The patient can experience symptoms such as hallucinations, delusions, and show extremely disordered thinking and behaviour that may hinder their daily activities.

 

Rising Prevalence of Mental Disorders

With the growing geriatric population, the number of cases of mental disorders is increasing as old people are more prone to such diseases.

 

Increasing Adoption of Long-Acting Injectables

Long acting injectables are growing in adoption due to concerns related to non-adherence to oral schizophrenia medication and the potential for relapses and psychotic symptoms. LAIs have a lower rate of non-adherence as they have fewer adverse effects compared to oral medications.

 

Increasing Efforts in Research and Development for Drug Development

Manufacturers have increased their research and development activities with the rise in the number of clinical trials in support of the development of novel treatments for schizophrenia.

 

Increasing Utilisation of Single-Cell Screening to Offer Lucrative Opportunities to the Market

Healthcare companies are innovating medication manufacturing by utilising high-content single-cell screenings. The development of new potential drugs would be done on a live cellular function model, which will help manufacturers to develop drugs in less time and at effective pricing.

 

Major Issues with Non-Adherence of Oral Drugs Can Challenge the Market Growth

Majority of the currently available oral drugs for schizophrenia have limited efficacy and can result in negative symptoms with a possibility of relapse in case of non-adherence. Some case may even show severe consequences.

 

Market Analysis

 

schizophrenia drugs market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on therapeutic class, the market can be segmented into second-generation antipsychotics and third-generation antipsychotics, among others. Based on treatments, it can be bifurcated into oral and injectables. Based on distribution channels, they can be divided into hospital pharmacies, retail pharmacies, and online, among others. The regional markets for the schizophrenia drugs market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. 

 

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global schizophrenia drugs market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans. 

 

  • Eli Lilly and Company
  • AbbVie Inc.
  • Alkermes PLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Others

 

Treatments in the Global Schizophrenia Drugs Market 

Based on treatment, the market for schizophrenia drugs can be bifurcated into oral and injectables. With the development of new key products for the treatment of schizophrenia as a result of the growing number of people suffering from the disease, the injectable segment is expected to hold a major share of the market.

 

Additionally, several key players in the market have started making substantial investments in research and development for novel treatment solutions.

 

Injectable-based schizophrenia medications, particularly long-acting injectables, are increasingly gaining popularity owing to their benefits and fewer adverse effects. They also help in suppressing the drawbacks associated with oral treatments. This development in schizophrenia drugs can help the market to grow further with improved patient outcomes and fewer relapses.

 

Distribution Channels for Schizophrenia Drugs

Based on distribution channels, the market bifurcations include hospital pharmacies, retail pharmacies, and online, among others.

 

The hospital pharmacy segment is expected to dominate the market, owing to the existence of trained psychiatrists who continue to operate in large hospitals and an increasing number of people with schizophrenia, as well as the increase of long-acting injectables, which physicians may utilise in their normal practice.

 

Following the hospital pharmacy, the online segment is expected to register the highest CAGR owing to the rapid expansion of internet services and smart devices around the world. People are also shifting towards online services due to the convenience of filling up prescriptions from home.

 

schizophrenia drugs market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Eli Lilly and Company is a pharmaceutical company based in the United States, with their headquarters in Indiana. They distribute their products in approximately 125 countries. The company has been in service since 1876. The company works on multiple diseases including Alzheimer’s, Cancer, Diabetes, Immunology, Obesity, and Pain.

 

AbbVie Inc. is an American pharmaceutical research and development company, which was founded in 2013. They provide therapeutic services for various areas of disease such as neuroscience, virology, oncology, immunology, and eye care. The company is increasingly invested to develop and deliver new medications.

 

Alkermes PLC is one of the key global biopharmaceutical companies, which was founded in 1987 and is headquartered in Ireland. The company is engaged in the development of innovative medicines in the medical field of neuroscience and oncology.

 

Other Key players include Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapeutic Class
  • Route of Administration
  • Distribution Channels
  • Region
Breakup by Therapeutic Class
  • Second-generation Antipsychotics
  • Third-generation Antipsychotics
  • Others
Breakup by Route of Administration
  • Oral
  • Injectables
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Eli Lilly and Company
  • AbbVie Inc.
  • Alkermes PLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Bristol Myers Squibb
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Vanda Pharmaceuticals Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Schizophrenia Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Schizophrenia Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Schizophrenia Epidemiology (2016-2031)
    5.3    Europe Schizophrenia Epidemiology (2016-2031)
    5.4    Asia-Pacific Schizophrenia Epidemiology (2016-2031)
    5.5    Latin America Schizophrenia Epidemiology (2016-2031)
    5.6    Middle East & Africa Schizophrenia Epidemiology (2016-2031)
6    Global Schizophrenia Drugs Market Overview
    6.1    Global Schizophrenia Drugs Market Historical Value (2017-2023)
    6.2    Global Schizophrenia Drugs Market Forecast Value (2024-2032)
7    Global Schizophrenia Drugs Market Landscape
    7.1    Schizophrenia Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Schizophrenia Drugs: Product Landscape
        7.2.1    Analysis by Therapeutic Class
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by Distribution Channels
8    Schizophrenia Drugs Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Schizophrenia Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Schizophrenia Drugs Market Segmentation
    11.1    Global Schizophrenia Drugs Market by Therapeutic Class
        11.1.1    Market Overview
        11.1.2    Second-generation Antipsychotics
        11.1.3    Third-generation Antipsychotics
        11.1.4    Others
    11.2    Global Schizophrenia Drugs Market by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral
        11.2.3    Injectables
    11.3    Global Schizophrenia Drugs Market by Distribution Channels
        11.3.1    Market Overview
        11.3.2    Hospital Pharmacies
        11.3.3    Retail Pharmacies
        11.3.4    Online     
        11.3.5    Others
    11.4    Global Schizophrenia Drugs Market by Region
        11.4.1    Market Overview
        11.4.2    North America
        11.4.3    Europe 
        11.4.4    Asia Pacific
        11.4.5    Latin America
        11.4.6    Middle East and Africa
12    North America Schizophrenia Drugs Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Schizophrenia Drugs Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Schizophrenia Drugs Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Schizophrenia Drugs Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Schizophrenia Drugs Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Eli Lilly and Company
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    AbbVie Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Alkermes PLC
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Otsuka Pharmaceutical Co., Ltd.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Johnson & Johnson Services, Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Pfizer Inc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    AstraZeneca
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Bristol Myers Squibb
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Sumitomo Dainippon Pharma Co., Ltd.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Vanda Pharmaceuticals Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Schizophrenia Drugs - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market is expected to grow at a CAGR of 3.9% during the period 2024-2032.

The market is driven by the increasing number of cases of schizophrenia and the wide adoption of long-acting injectables due to their benefits of reduced relapse of the patient.

The rising investment and industrial collaborations in the development of novel treatments for schizophrenia are key trends followed in the market.

The regional markets for the global schizophrenia drugs market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

The different therapeutic classes in the market include second-generation antipsychotics and third-generation antipsychotics, among others.

The different types of treatment in the market include oral and injectables.

The distribution channels used for schizophrenia drugs include hospital pharmacies, retail pharmacies, and online, among others.

The key players in the market include Eli Lilly and Company, AbbVie Inc., Alkermes PLC, Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER